key: cord-0887722-uepxbags authors: Desheva, Yulia; Mamontov, Andrey; Petkova, Nadezhda; Karev, Vadim; Nazarov, Peter title: Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice date: 2020-08-08 journal: Life Sci DOI: 10.1016/j.lfs.2020.118230 sha: f3866b52631731d60570c1eb287b9a664a649c26 doc_id: 887722 cord_uid: uepxbags Here we evaluate the role of mast cells in infection with influenza A/H5N1 virus in immunized mice. CBA mice were immunized intramuscularly with formalin-inactivated A/Vietnam/1194/2004 (H5N1)NIBRG-14 (H5N1). Serum samples were obtained on days 7, 12, 14, 21 after immunization. At day 14, the mice were infected intranasally with the A/Indonesia/5/2005 (H5N1)IDCDC-RG2 (H5N1) influenza virus with half of the animals receiving a mixture of the antihistamines. 67% of the vaccinated mice were protected from the lethality compared to 43% in the PBS-immunized group. Administration of antihistamines increased survival up to 85%–95%. Immunohistochemical examination using CD117 staining of the lungs demonstrated a larger quantity of activated mast cells after infection of immunized mice compared to mock-immunized mice. This was correlated to increased histamine level in the lungs and blood. Our experimental results suggest the involvement of mast cells and the histamine they produce in the pathogenesis of influenza infection in case of incomplete formation of the immune response to vaccination and mismatch of the vaccine and infection influenza viruses. Avian H5 influenza viruses (the genus Influenzavirus, the family Orthomyxoviridae) presents great concern to health authorities around the world due to sporadic human infections causing serious illness and high mortality [1] . The A/H5N1 influenza virus was considered to have potential to cause a possible pandemic after it had been isolated from a child who died of viral pneumonia during a massive chicken outbreak in Hong Kong in 1997 [2] . According to the WHO data for the period from 2003 to 2019, the mortality rate from laboratory confirmed A/H5N1 influenza was 30%66% [https://www.who.int/influenza/human_animal_interface/2020_MAY_tableH5N1.pdf?ua=1]. From 2014 to 2019, the incidence and mortality rate of H5 influenza decreased, and no human cases of this disease have been registered anywhere in the world in 2020 [3] . The clinical features of a human infection caused by highly pathogenic A/H5N1 viruses are characterized not only by primary viral pneumonia, but also by complications with acute distress syndrome and multiple organ lesions [5] . severe course of infection. ADE is characteristic of dengue fever, in which it received attention and was first described [7] , but is also observed in other viral infections [8] [9] [10] [11] including Zika, Ebola, HIV, respiratory syncytial virus and SARS-CoV infections [12, 13] . Instead of a complete neutralizing antiviral immunity, so-called "sensitization" may occur as a result of primary infections with heterotypic viruses of the same genera, as well as divergent antigenic variants of the infectious virus during chronic infections, or after immunizations resulting in incomplete protective immunity. This can lead to an antibodydependent increased secondary infection [14] . There is an assumption that if there is a lack of virus-neutralizing antibodies, the nonneutralizing influenza-specific antibodies may participate in cellular reactions [15] . During the 2009 influenza pandemic, the use of seasonal vaccines and the presence of non-neutralizing antibodies against А/H1N1pdm09 correlated with an increased risk of a more severe flu-like illness in infected people [16] . The low avidity of non-neutralizing antibodies can lead to the formation of immune complexes and the activation of the complement cascade [17] , which caused severe disease in young people during the 2009 pandemic [18] . Scientific literature discusses the ADE phenomenon with the participation of immune complexes of IgG antibodies, which mediate exacerbation of diseases associated with a wide range of pathogens. The biological activity of immune complexes and ADE complicate the development of novel vaccines. The aim of the study was to evaluate the role of antibodydependent mast cell reactions in influenza-sensitized mice. Ethics statement. All procedures involving animals were performed according to the "Rules Laboratory Vero-certified vaccine-producing cells and laboratory protocols that take into account that the end use of the vaccine is administration to humans. The WHO Influenza Center recommends these strains for the preparation of inactivated influenza vaccines against avian influenza. Viruses contain modified H5 subtype hemagglutinin and are safe for humans. The viruses used in the study were cultivated in the allantoic cavity of 10-day-old developing chicken embryos (Skvoritsy poultry farm, Leningrad region, Russian Federation). Inactivated whole virus vaccine was prepared as previously described [19] from Simultaneously with the infection, half of the immune mice were given intraperitoneal injections with a mixture of histamine receptor blockers H1 and H2, сhloropyramine (Egis, Guyancourt, France) and quamatel (Gedeon Richter, Budapest, Hungary), each 6.7 mg/kg body weight, in a volume of 0.1 ml, or PBS in the same volume. The experimental design is shown in Fig. 1 . To determine the viral titer in the lungs, the samples were collected from mice at 72 h after viral infection, homogenized in PBS containing 100 U/ml penicillin, 100 μg/ml streptomycin and centrifuged for 10 min at 6000 g. The viral titers were calculated as a log 10 of the fifty percent embryonic infectious doses (EID 50 ) using hemagglutination as the endpoint, as described previously [19] . To determine the histamine levels in the lungs and blood of mice by ELISA, samples were collected on the 5 th day after infection with the A/Indonesia/5/2005(H5N1) IDCDC-RG2 virus. Histamine production was evaluated using the EIA Histamine kit (Beckman Coulter, Brea, United States) according to the manufacturer's instructions. For immunohistochemical examination, lung sections were obtained at day 8 after viral infection, fixed in 10% neutral buffered formalin and embedded in paraffin. Immunohistochemical staining for CD117 (mast cell marker) was done using rabbit polyclonal antibodies (mAb) to CD117 (Agilent, Santa Clara, United States), additional staining was performed using toluidine blue. Additionally, sections were stained with hematoxylin and eosin (H&E). Statistics. Data was processed using Statistica software, version 6.0 (StatSoft, Inc. Tulsa, Oklahoma, USA) and graphics data were generated using Prism 8 (GraphPad software, San Diego, USA). Means and standard errors of means (SEM) were calculated to represent virus titers. Reciprocal antibody titers were expressed as log 2 and presented as mean±SEM. To compare two independent groups, we used a Mann-Whitney U-test. To compare multiple independent groups, we used a Kruskal-Wallis ANOVA test. The p-value <0.05 was considered to be statistically significant. Immunogenicity. On day 12 after immunization the levels of HI antibodies to vaccine and infecting viruses were lower than 1:40 (Fig 2, A) , i.e. did not reach a protective level which is associated with at least a 55% reduction in the risk of influenza [20] . degranulated mast cells was found in visual field (Fig. 5, A, B , C, mast cells are indicated by arrows). After administration of antihistamines to immune mice during infection, mast cells were also detected in the peribronchial region, from 2 to 10 in the visual field (Fig. 6, A) . In this case, both intact and degranulated mast cells were detected (Fig. 6, C, D) . The data obtained do not allow us to conclude that the administration of antihistamines reliably affects the number of mast cells in the lungs and their localization. We assume that antihistamines, by blocking H receptors on histamine-sensitive structures, may abolish the reaction of vessels to histamine and thereby reduce blood cell transudation from vessels. Hematoxylin-eosin staining revealed the presence of peribronchial infiltrates in case of infection of immunized mice, both without antihistamines ( Fig. 5 , E) and when antihistamines were used (Fig. 6, В) , in contrast to infection of nonimmunized mice (Fig. 4 , E) when peribronchial infiltrates were not detected. The histamine content in the lungs and blood serum. The content of histamine secreted by activated lung tissue mast cells and blood basophiles was evaluated in the lungs and blood serum of mice on the 5 th day after infection with A/Indonesia/5/2005(H5N1) IDCDC-RG2. As the data in Figure 7 show, the histamine content in the lungs was higher than in the blood. In mice from all vaccine groups infected with the A/Indonesia/5/2005(H5N1) IDCDC-RG2 virus on the 14 th day after immunization, the histamine level in the lungs was increased compared to control non-vaccinated mice that did not receive the virus. Moreover, the histamine level in the lungs and in the sera significantly differed from the control mice only in immune mice (Fig. 7, B) . This may indicate that the release of histamine was induced not only by the development of a viral infection, but also by the antibody + virus immune complex as IgG-containing immune complexes are able to activate mast cells to release histamine [22, 23] . The administration of antihistamines reduced the histamine content in the lungs of immune animals infected with the drifted A/H5N1 virus very slightly. The introduction of antihistamines to infected immune animals slightly decreased the histamine content in the blood, although the differences were not statistically significant. Since it was found that on the 21 st day the antibody response exceeded that on the 14 th day, we conducted an experiment with the infection of mice at a later day after immunization. Three weeks after vaccination, 75% of vaccinated animals were protected from mortality due to A/Indonesia/5/2005(H5N1) IDCDC-RG2 virus infection (P=0.023 compared to mock-vaccinated animals, Fig 8, A) while in the group of non-immunized animals only 12.5% survived. The titers of the infectious virus in the lungs and weight dynamics were significantly different from those in non-immunized animals (Fig. 8, B, C) . Thus, vaccination of mice using inactivated A/H5N1 vaccine provided more pronounced protection on the 21 st day compared to the 14 th day. In the case of a more complete immune response of antibodies, which are known to be the main protective factor for immunization with an inactivated vaccine, the protective effect of vaccination should prevail over possible antibody-dependent adverse reactions. The scientific literature widely discusses the involvement of IgG-containing immune complexes in ADE development, which may mediate exacerbation of diseases associated with a wide range of pathogens. Non-neutralizing antibodies with low avidity to influenza virus that does not match the vaccine can activate the complement cascade and, in combination with dysregulation of cytokines, cause a damaging effect in the absence of neutralizing immunity [24] . Previously, it was shown that whole inactivated A/H1N2 influenza vaccines may provide only partial protection against drift variants of HA subtype in pigs, but also may induce vaccineassociated enhanced respiratory disease [25] . This study investigated the immune response HA is poorly immunogenic and may need either booster or adjuvanted immunization for eliciting protective titer. In our previous studies in mice, it was shown that immunization with an inactivated influenza vaccine (IIV) of A/H5N2 subtype elicited neutralizing antibodies to the homologous H5 virus one month after a single vaccination [30] . In the same study, it was shown that after double immunization with A/Hong Kong/213/2003(H5N1) IIV with aluminum, neutralizing antibodies to the antigenic variant A/Vietnam/1203/2004 (H5N1) were detected two months after booster immunization. In those cases, we were dealing with completed immunization, when antibodies were detected a month or more after immunization. The current study had other tasks, because, on the contrary, we simulated the so-called "sensitization" of mice. For this reason, serum antibodies were determined even before the development of a fullfledged immune response, and then a challenge was performed. Along with this we were interested in the further development of the immune response up to three weeks after immunization. It was confirmed that, on the 21 st day after immunization, serum levels of serum IgG for the test virus were significantly higher than those on the 14 th day (Fig. 2, C) . As shown in Fig. 2 Previously it was shown that in mice influenza infection or vaccination did not increase the level of serum IgE compared to non-immunized and uninfected animals [33] . Repeated sensitization of mice with ovalbumin was needed during bronchial asthma modeling to achieve In a number of infections, the presence of specific IgG antibodies and their complexes with an antigen is associated with pathological reactions [35] . However, the mechanisms, ways of development and prevention of immunocomplex pathology are not fully understood. Immunization with vaccines based on avian influenza viruses is often accompanied by reduced immunogenicity in both animals and humans compared to seasonal vaccines [36, 37] . The A/Vietnam/1194/2004(H5N1) NIBRG-14-based inactivated influenza vaccine was previously demonstrated to be only moderately immunogenic in humans as 2 doses of 45 μg of HA-the dose used in those study-resulted in HI seroconversion in only 41%-56% of study subjects in phase 1 clinical trials [36] . Therefore, the formation of a certain part of nonneutralizing antibodies that could take part in immune-complex reactions cannot be ruled out. Moreover, if virus-specific antibodies are the main protective component for immunization with inactivated influenza vaccines, the time interval before the formation of a complete antibody immune response, i.e. between the second and third week after immunization, should be considered. If an infection occurs during this interval, it is possible that the use of antihistamines can help reduce the severity of the consequences of such an infection. In Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness Whole-of-society approach for influenza pandemic epicenter Containment exercise in Indonesia Emergence and dissemination of clade 2.3.4.4 H5Nx influenza viruses -how is the Asian HPAI H5 lineage maintained. Current Opinion in Virology Avian influenza A (H5N1) infection in humans. The New England journal of medicine The total influenza vaccine failure of 1947 revisited: major intrasubtypic antigenic change can explain failure of vaccine in a post-World War II epidemic Cross-reacting antibodies enhance dengue virus infection in humans Biologic evidence required for Zika disease enhancement by Dengue antibodies Antibody-dependent enhancement of Ebola virus infection Antibody-dependent enhancement and the risk of HIV infection Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus How innate immune mechanisms contribute to antibody-enhanced viral infections Antibody-dependent cellular cytotoxicity and influenza virus. Current opinion in virology Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during spring-summer 2009: four observational studies from Canada. PLoS medicine A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nature medicine Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. BMC infectious diseases Antigen/IgG immune complex-primed mucosal mast cells mediate antigen-specific activation of co-cultured T cells OxLDL-IgG immune complexes induce expression and secretion of proatherogenic cytokines by cultured human mast cells Vaccine-associated enhanced respiratory disease is influenced by haemagglutinin and neuraminidase in whole inactivated influenza virus vaccines Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Science translational medicine Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge Mast cells-key effector cells in immune responses The human mast cell Mast-cell responses to pathogens Cross-protective immunity in mice induced by liveattenuated or Properties of mouse and human IgG receptors and their contribution to disease models. Blood, The Journal of the Immunization with live influenza viruses in an experimental model of allergic bronchial asthma: infection and vaccination. Influenza and other respiratory viruses Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections Active anaphylaxis in IgE-deficient mice Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.The authors thank Maria Kozlova for English editing. The authors declare no commercial or financial conflict of interest.References.